Анализ влияния антигипертензивных препаратов на регресс гипертрофии левого желудочка

DOI: https://dx.doi.org/10.18565/cardio.2014.3.82-91

Козиолова Н.А., Шатунова И.М.

ГБОУ ВПО Пермская государственная медицинская академия им. акад. Е.А. Вагнера Минздрава России, Пермь; Поликлиника ОАО «ГАЗПРОМ», Москва
В обзорной статье отражена ведущая роль комбинированного лечения блокаторами ренин-ангиотензин-альдостероновой системы и антагонистами кальция дигидропиридинового ряда в снижении массы миокарда левого желудочка. Показаны преимущества фиксированных комбинаций в лечении больных артериальной гипертонией, в том числе при гипертрофии левого желудочка. Продемонстрированы преимущества низкого риска развития побочных эффектов и высокой приверженности пациентов к лечению при использовании антагонистов рецепторов к ангиотензину II в сравнении с другими классами антигипертензивных препаратов при выборе стартовой терапии больных артериальной гипертонией, в том числе при комбинации лекарственных средств.
Ключевые слова: антигипертензивная терапия, гипертрофия левого желудочка
Читать статью в
"Библиотеке Врача"

Литература


  1. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290—300.

  2. Hong B.K., Park C.G., Kim K.S. et at. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. Am J Cardiovasc Drugs 2012;12:189—195.

  3. Park C.G., Youn H.J., Chae S.C. et al. Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. Am J Cardiovasc Drugs 2012;12:35—47.

  4. Lombardo M., Zaini G., Pastori F. et al. Left ventricular mass and function before and after antihypertensive treatment. J Hypertens 1983;1:215—219.

  5. Wetzchewald D., Klaus D., Garanin G. et al. Regression of left ventricular hypertrophy during long-term antihypertensive treatment — a comparison between felodipine and the combination of felodipine and metoprolol. J Intern Med 1992;231:303—308.

  6. Mancia G., Zanchetti A., Agabiti-Rosei E. et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997;95:1464—1470.

  7. Miller A.B., Reichek N., St John Sutton M. et al. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens 2010;4:302—310.

  8. Cruickshank J.M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85—90.

  9. Zhou M.S., Jaimes E.A., Raij L. Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats. J Cardiovasc Pharmacol 2006;48:857—861.

  10. Dahlöf B., Gosse P., Guéret P. et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063—2070.

  11. de Luca N., Mallion J.M., O’Rourke M.F. et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004;17:660—667.

  12. Neutel J.M., Smith D.H., Weber M.A. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004;17:37—42.

  13. Devereux R.B., Palmieri V., Sharpe N. et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001;104:1248—1254.

  14. Boydak B., Nalbantgil S., Yilmaz H. et al. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension. Saudi Med J 2004;25:1975—1978.

  15. Martina B., Dieterle T., Weinbacher M., Battegay E. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology 1999;92:110—114.

  16. Dahlöf B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895—906.

  17. Gerstein H.C. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002;18:S82—85.

  18. Wing L.M., Reid C.M., Ryan P. et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583—592.

  19. Hansson L., Lindholm L.H., Ekbom T. et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 (STOP- Hypertension 2) study. Lancet 1999;354:1751—1756.

  20. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of ACE inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP). Lancet 1999;353:611—616.

  21. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805—2816.

  22. Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995—1003.

  23. Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875—886.

  24. Schrader J., Lüders S., Kulschewski A. et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218—1226.

  25. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal ands cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861—819.

  26. Parving H.H., Lehnert H., Bröchner-Mortensen J. et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870—878.

  27. Viberti G., Wheeldon N.M. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672—678.

  28. Berl T., Hunsicker L.G., Lewis J.B. et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542—549.

  29. Imai E., Chan J.C., Ito S. et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011;54:2978—2986.

  30. Kostis J., Algert C., Woodward M. et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. Blood Pressure Lowering Treatment Trialists’ Collaboration. J Hypertens 2007;25:951—958.

  31. Derosa G., Maffioli P. Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure. Expert Rev Cardiovasc Ther 2013;11:719—728.

  32. Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217—2225.

  33. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022—2031.

  34. Fretheim A., Odgaard-Jensen J., Brørs O. et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med 2012;10:33.

  35. Neal B., MacMahon S., Chapman N. et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955—1964.

  36. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527—1535.

  37. Jamerson K., Weber M.A., Bakris G.L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.N Engl J Med 2008;359:2417—2428.

  38. Bakris G., Briasoulis A., Dahlof B. et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol 2013;112:255—259.

  39. Weber M.A., Jamerson K., Bakris G.L. et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013;381:537—545.

  40. Koyanagi R., Hagiwara N., Yamaguchi J.I. et al. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: A subanalysis of the HIJ-CREATE study. J Cardiol 2013. pii: S0914-5087(13)00142-1.

  41. Sawada T., Yamada H., Shiraishi J. et al. Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study. Clin Exp Hypertens 2012;34:153—159.

  42. Redón J., Trenkwalder P.R., Barrios V. Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension. Expert Opin Pharmacother 2013;14:155—164.

  43. Yamamoto E., Kataoka K., Dong Y.F. et al. Calcium channel blockers, more than diuretics, enhance vascular protective effects of angiotensin receptor blockers in salt-loaded hypertensive rats. PLoS One 2012;7:e39162.

  44. Matsui Y., O'Rourke M.F., Hoshide S. et al. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 2012;59:1132—1138.

  45. Matsui Y., Eguchi K., O'Rourke M.F. et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009;54:716—723.

  46. Ishimitsu T., Ohno E., Nakano N. et al. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease. Clin Exp Hypertens 2011;33:366—372.

  47. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009;23:503—511.

  48. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201—207.

  49. Kuti E.L., Baker W.L., White C.M. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker. Curr Med Res Opin 2007;23:1239—1244.

  50. Lindholm L.H., Ibsen H., Borch-Johnsen K. et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879—1886.

  51. Bakris G.L., Sarafidis P.A., Weir M.R. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173—1181.

  52. Martinez-Martin F.J., Rodriguez-Rosas H., Peiro-Martinez I. et al. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011;25:346—353.

  53. Cooper-Dehoff R.M., Bird S.T., Nichols G.A. et al. Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study. J Am Heart Assoc 2013;2:e000125.

  54. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281—1357.

  55. Powers B.J., Coeytaux R.R., Dolor R.J. et al. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med 2012;27:716—729.

  56. Toh S., Reichman M.E., Houstoun M. et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582—1589.

  57. Mancia G., Schumacher H. Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials. Patient Prefer Adherence 2012;6:1—9.

  58. Matchar D.B., McCrory D.C., Orlando L.A. et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16—29.

  59. Powers B., Greene L., Balfe L.M. Updates on the treatment of essential hypertension: a summary of AHRQ’s comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. J Manag Care Pharm 2011;17:S1—14.

  60. Esposti L.D., Saragoni S., Batacchi P. et al. Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years. Clinicoecon Outcomes Res 2010;2:113—120.

  61. Kronish I.M., Woodward M., Sergie Z. et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011;123:1611—1621.

  62. Böhm M., Schumacher H., Laufs U. et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013;166:306—314.

  63. Anan F., Takahashi N., Ooie T. et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 2005;61:353—359.

  64. Grandi A.M., Solbiati F., Laurita E. et al. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens 2008;21:231—237.

  65. Cowan B.R., Young A.A., Anderson C. et al. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).Am J Cardiol 2009;104:1484—1489.

  66. Verdecchia P., Sleight P., Mancia G. et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009;120:1380—1389.

  67. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547—1559.

  68. Mann J.F., Schmieder R.E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547—553.

  69. Mallat S.G. Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence? Cardiovasc Diabetol 2013;12:108.

  70. Makani H., Bangalore S., Desouza K.A. et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013;346:f360.

  71. Susantitaphong P., Sewaralthahab K., Balk E.M. et al. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 2013;26:424—441.

  72. Fernandez Juarez G., Luño J., Barrio V. et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis 2013;61:211—218.

  73. Taniguchi I., Kawai M., Date T. et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006;70:995—1000.

  74. Pitt B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831—1838.

  75. Solomon S.D., Appelbaum E., Manning W.J. et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530—537.

  76. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308—347.

  77. Fogari R., Zoppi A., Mugellini A. et al. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opin Pharmacother 2012;13:1091—1099.

  78. Chobanian A.V., Bakris G.L., Black H.R. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206—1252.

  79. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713—719.

  80. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399—407.

  81. Dickson M., Plauschinat C.A. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008;8:45—50.

  82. Zeng F., Patel B.V., Andrews L. et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010;26:2877—2887.

  83. Mallat S.G., Itani H.S., Tanios B.Y. Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control 2013;6:69—78.

  84. Smith D.H. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs 2007;7:413—422.

  85. Gerc V., Begović B., Vehabović M. et al. Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn J Basic Med Sci 2008;8:214—219.

  86. Чазова И.Е., Ратова Л.Г., Дмитриев В.В. и др. Терапия больных с артериальной гипертензией фиксированной дозой комбинации лозартана и гидрохлоротиазида. Влияние на 24 часа кровяного давления и гипертрофию левого желудочка. Кардиология 2003;10:60—65.

  87. Недогода С.В., Марченко И.В., Chaliabi Т.А. и др. Сравнительная эффективность комбинаций фиксированных доз периндоприла с индапамидом и каптоприла с гидрохлоротиазидом у пациентов с высоким риском артериальной гипертензии. Кардиология 2005; 11:24—26.

  88. Koziolova Н.А., Шатунова И.М., Лазарев И.А. Факторы риска развития гипертрофии левого желудочка у больных с гипертонической болезнью при высокой приверженности к лечению. Кардиология 2012;4:25—30.


Об авторах / Для корреспонденции

Сведения об авторах:
ГБОУ ВПО Пермская государственная медицинская академия им. акад. Е.А. Вагнера Минздрава России
Козиолова Н.А. - д.м.н., проф., зав. кафедрой пропедевтики внутренних болезней №2.
Поликлиника ОАО «ГАЗПРОМ», Москва
Шатунова И.М. - к.м.н., врач высшей категории, зав. кардиологическим кабинетом поликлиники.


Похожие статьи

К содержанию номера

Бионика Медиа   Apple Store